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vascular disease and remains the leading cause of death in the U.S.
(Tabas et al., 2015). Atherosclerotic plaques can be treated by revas-
cularization procedures, including angioplasty, stenting, or bypass
surgery, but microtrauma to the blood vessel during these procedures
can lead to a complication called intimal hyperplasia, a hyper-
proliferation of cells in the vascular lumen (Katz et al., 2015). Smooth
muscle cells (SMC), which comprise the muscular layer of arteries,
retain the remarkable ability to dedifferentiate in response to injury
and assume a repair phenotype. These SMC downregulate expression
of their characteristic contractile proteins and migrate from the vessel
wall into the lumen where they proliferate and secrete matrix proteins,
forming a ﬁbrotic scar (Liu et al., 2015). While local drug delivery with
drug-eluting stents has been effective in reducing intimal hyperplasia
in coronary arteries, intimal hyperplasia remains a major challenge in
diabetic patients and in peripheral blood vessels (Katz et al., 2015). In
this issue,Wang et al. present exciting ﬁndings that targeting epigenetic
“reader” proteins is a promising therapeutic strategy for preventing in-
timal hyperplasia.
Our understanding of the smooth muscle phenotypic switching that
underlies the intimal hyperplastic response has been largely at the tran-
scriptional level, but recent studies revealed roles for epigenetic regula-
tion, including DNA methylation and modiﬁcations of the histone
proteins that organizeDNA into chromatin. Collectively, these epigenet-
icmodiﬁcations,made by proteins referred to as “writers” and “erasers”,
govern chromatin accessibility to transcription factors (Liu et al. 2015).
The bromodomain and extraterminal domain (BET) family of reader
proteins serve as critical adaptors, recognizing histone acetylated lysine
residues and recruiting additional proteins to promote transcription
elongation (Shi and Vakoc, 2014). Wang et al. demonstrate that BET
proteins play an important role in intimal hyperplasia. The authors
found that the BET protein BRD4 was expressed at low levels in normal
rat carotid artery but was highly induced in SMC following balloon an-
gioplasty. BRD4was also present in human vein and artery graft intimal
hyperplastic lesions but not in normal vessels. Themost excitingﬁnding
was that a BET-speciﬁc bromodomain inhibitor, JQ1, reduced intimalDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.09.045.
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cultured aortic SMC in response to PDGF-BB, a growth factor that medi-
ates much of the intimal hyperplastic response. While this inhibitor
targets multiple BET proteins, knockdown experiments implicated
BRD4, but not BRD2 or BRD3, in SMC proliferation. Their data support
amodelwhere BRD4 expression is induced by PDGF-BB, but also poten-
tiates the signaling of its cognate receptor, PDGFRβ. An interesting ﬁnd-
ing was that PDGFRα was dramatically upregulated in the luminal
hyperplastic SMC following angioplasty and its expression depended
on BET protein function in cultured SMC. The role of PDGFRα and its li-
gands PDGF-AA or –CC in intimal hyperplasia is not well understood,
but this work suggests that further investigation in this area is warrant-
ed. Other questions raised by this work include whether there may be
roles for BRD2 or BRD3 (also inhibited by JQ1) in SMC biology, identify-
ing the key target genes regulated by BRD4 in intimal hyperplasia, and
determining the mechanisms that confer the speciﬁc interaction of
BRD4 with target genes.
A concern for many potential inhibitors of restenosis is that their
anti-proliferative effects are not speciﬁc to SMC and can therefore also
inhibit proliferation of endothelial cells (EC) that line the lumen. De-
layed re-endothelialization of the treated area creates a thrombogenic
surface for platelet adhesion, which can cause an acute severe occlusion
of the vessel leading to myocardial infarction, stroke, or peripheral tis-
sue ischemia (Katz et al., 2015). Importantly, the BET inhibitor JQ1 did
not appear to promote thrombosis in vivo, and even exerted protective
effects on EC in culture, preventing apoptosis and migration defects in
response to inﬂammatory cytokines (Wang et al., 2015). The proﬁle of
BET domains expressed in EC and their roles in endothelial function
are not yet well characterized, but these preliminary experiments sug-
gest that BET inhibitors may be endothelium-sparing.
While this is theﬁrst study to implicate epigenetic reader proteins in
intimal hyperplasia, several recent studies have also identiﬁed roles for
BRD4 in other diseases of SMC remodeling. BRD4 was also upregulated
in human pulmonary arterial hypertension (PAH), and JQ1 treatment
reversed PAH in a rat model. Mechanistically, microRNA-204 targeted
BRD4, and BRD4 regulated cell cycle and survival genes (Meloche
et al., 2015). BRD4 was also implicated in TGFβ responses in airway
SMC from asthmatic patients, regulating chemokine and cytokine ex-
pression (Perry et al., 2015). Intriguingly, BET proteins may hold prom-
ise for treating systemic atherosclerosis, as BET inhibitors (RVX-208)the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1575A.C. Ostriker, K.A. Martin / EBioMedicine 2 (2015) 1574–1575have been found to increase expression of the HDL particle protein
ApoA-I, and to induce cholesterol efﬂux in mice, non-human primates,
and humanpatients. A recent Phase 2b trial (ASSURE) of RVX-208, how-
ever, did not demonstrate signiﬁcant differences in HDL, LDL, CRP, or
atheroma volume (Nicholls et al., 2015). Whether other parameters
such as SMC-mediated plaque stability are beneﬁcially affected is not
known. BET inhibitors are also in clinical trials for multiple types of ma-
lignancies, targeting MYC, BCL2, and other oncogenes (Shi and Vakoc,
2014). Collectively, emerging studies suggest a common theme for
BRD4 in SMC proliferative responses. As BET inhibitors have shown
safety and promise in clinical trials, further studies are warranted to un-
derstand the target genes, mechanisms of action, and therapeutic
potential.
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